Bolt Biotherapeutics, Inc. (BOLT) Form 10-Q — Aug 11, 2026
Bolt Biotherapeutics' Q2 2026 10-Q discloses substantial doubt about its ability to continue as a going concern, with management stating its $18.1 million of cash, cash equivalents and marketable securities as of June 30, 2026 will not fund operations for at least one year and may only stretch into the first quarter of 2027. The company reported a Q2 net loss of $7.7 million ($4.57 per share) and a six-month net loss of $15.0 million ($8.88 per share), narrowed from $8.6 million and $19.6 million a year earlier after an October 2025 restructuring cut its workforce by roughly 50%. Accumulated deficit stands at $475.7 million against $40.3 million in total assets and no outstanding debt.
Key figures
- Eps
- -$8.88 six months; -$4.57 Q2 2026
- Revenue
- $31,000 six months ended 6/30/26 ($5,000 in Q2 2026); down from $3.0M and $1.8M a year ago
- Net Income
- -$14.96M six months ended 6/30/26; -$7.72M Q2 2026
- Total Debt
- 0
- Total Assets
- 40344000
- Cash Position
- 18100000
- Shares Outstanding
- 1926345
- Cash Runway
- into first quarter 2027
- Reverse Split Ratio
- 1-for-20 (effected June 6, 2025)
- Accumulated Deficit
- 475700000
- Cash And Equivalents
- 12860000
- Stockholders Equity
- 12640000
- Workforce Reduction
- approximately 50% of workforce (~20 employees)
- Impairment Charges Q2 2026
- 808000
- Weighted Avg Shares Q2 2026
- 1690529
- Total Lease Payments Remaining
- 28859000
- Restructuring Charge October2025
- 1500000
Price after filing
Close on the filing date to close N calendar days later (from $3.99). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.